FY2025 Earnings Estimate for Harrow Issued By HC Wainwright

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Harrow in a report released on Wednesday, November 12th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.61 per share for the year, up from their prior forecast of $0.24. HC Wainwright has a “Buy” rating and a $69.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q4 2025 earnings at $0.40 EPS, Q1 2026 earnings at $0.02 EPS and Q4 2026 earnings at $0.51 EPS.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.11. The business had revenue of $71.64 million for the quarter, compared to analyst estimates of $73.70 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%.

Other research analysts have also issued research reports about the company. BTIG Research reaffirmed a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Wednesday, September 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Wednesday, October 8th. Lake Street Capital raised their price target on Harrow from $42.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a report on Friday, September 12th. Finally, LADENBURG THALM/SH SH upped their price objective on shares of Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $71.43.

Harrow Stock Performance

Harrow stock opened at $37.89 on Friday. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. The firm has a market cap of $1.40 billion, a P/E ratio of -151.56 and a beta of 0.19. Harrow has a 1-year low of $20.85 and a 1-year high of $50.72. The firm has a 50-day moving average of $40.72 and a 200-day moving average of $34.89.

Institutional Trading of Harrow

Hedge funds have recently modified their holdings of the business. Quarry LP bought a new position in shares of Harrow in the 1st quarter worth about $32,000. Raymond James Financial Inc. purchased a new position in Harrow during the second quarter valued at $48,000. State of Alaska Department of Revenue bought a new stake in Harrow in the third quarter worth $83,000. State of Wyoming bought a new position in shares of Harrow during the first quarter valued at $97,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after purchasing an additional 2,615 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.